港股異動 | 獲多家券商唱好 丘鈦科技逆勢漲近4%
格隆匯10月15日丨丘鈦科技(1478.HK)逆勢漲3.8%,報9.8港元,暫成交7332萬港元,最新總市值112億港元。第一上海指,公司9月份的攝像頭出貨量為38.1kk,已接近公司年中約42kk/月的產能,預計到年底,隨着三期自動化工廠的投產,以及印度模組公司的投產,公司的CCM產能將達到50kk/月,規模優勢會繼續帶動成本效益,增益公司的利潤水平,公司全年業績增長可期,提升公司目標價至11.5港元,維持為買入評級。光大證券指,9月公司10MP以上攝像模組CCM及屏下指紋高端產品出貨量環比上升顯著,預計公司19年業績有望顯著超市場預期,且20年仍有望保持快速增長,上調目標價至12.1港元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.